Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their ...

On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new ...

A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data ...

The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who ...

Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said ...

Bristol Myers Squibb and Ideaya Biosciences both released detailed snapshots of early-stage data for cancer drugs targeting ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Elucida Oncology, a clinical-stage biotech led by former Pfizer executive Geno Germano, has shut down, Endpoints News has ...

GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine ...

A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...

The future of Telix Pharmaceuticals' new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO ...